{"id":"triamcinolone-xrg5029","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Adrenal suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators and reduced immune cell activation. The XRG5029 designation suggests this may be a modified or extended-release formulation of triamcinolone designed to optimize pharmacokinetics or reduce dosing frequency. As a corticosteroid, it broadly suppresses both innate and adaptive immune responses.","oneSentence":"Triamcinolone is a synthetic corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:07.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific Phase 3 indication unknown)"}]},"trialDetails":[{"nctId":"NCT03317015","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Rhinitis Allergic","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nasacort®"],"phase":"phase_3","status":"active","brandName":"triamcinolone XRG5029","genericName":"triamcinolone XRG5029","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone XRG5029 is a small molecule glucocorticoid receptor agonist, classified as an agonist. It is being studied for the treatment of perennial allergic rhinitis, specifically in comparison to fluticasone in a clinical trial.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-07-11T00:00:00.000Z","mah":"CHATTEM SANOFI","brand_name_local":"NASACORT","application_number":"NDA019798"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}